These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28074989)

  • 21. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
    Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
    Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualization of tamoxifen treatment for breast carcinoma.
    Binkhorst L; van Gelder T; Mathijssen RH
    Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
    Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
    Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer and antidepressant use.
    Andrade C
    J Clin Psychiatry; 2012 Sep; 73(9):e1156-7. PubMed ID: 23059156
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.
    Cronin-Fenton DP; Lash TL
    Expert Rev Clin Pharmacol; 2011 May; 4(3):363-77. PubMed ID: 21709817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do antidepressants reduce the effectiveness of tamoxifen?
    Breitbart W
    Psychooncology; 2011 Jan; 20(1):1-4. PubMed ID: 21182159
    [No Abstract]   [Full Text] [Related]  

  • 29. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.
    Jordan VC
    Steroids; 2007 Nov; 72(13):829-42. PubMed ID: 17765940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do some antidepressants decrease effect of tamoxifen?
    J Support Oncol; 2009; 7(4):147-8. PubMed ID: 19731582
    [No Abstract]   [Full Text] [Related]  

  • 31. Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction.
    Shin J; Hills NK; Finley PR
    Pharmacotherapy; 2020 Jun; 40(6):507-516. PubMed ID: 32342526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
    Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
    Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hot flash on tamoxifen metabolism.
    Goetz MP; Loprinzi CL
    J Natl Cancer Inst; 2003 Dec; 95(23):1734-5. PubMed ID: 14652227
    [No Abstract]   [Full Text] [Related]  

  • 34. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interactions between metoprolol and antidepressants].
    Molden E; Spigset O
    Tidsskr Nor Laegeforen; 2011 Sep; 131(18):1777-9. PubMed ID: 21946596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?
    Dieudonné AS; De Nys K; Casteels M; Wildiers H; Neven P
    Acta Clin Belg; 2014; 69(1):47-52. PubMed ID: 24635399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.